株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

GLYX-13 (大うつ病性障害)-予測と市場分析

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 305488
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
GLYX-13 (大うつ病性障害)-予測と市場分析 GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
出版日: 2014年05月30日 ページ情報: 英文 61 Pages
概要

大うつ病性障害(MDD)は世界で最も一般的な精神疾患の一つであり、その治療薬市場は競合が激しく、30を超える製品が上市されています。Eli Lillyの Cymbalta,大塚製薬/BMSのAbilifyといった主要製品の特許切れや、Lundbeck/武田医薬品のBrintellixなど最終段階のパイプライン製品の投入を目前に、市場は大きく動いています。GLYX-13は抗うつ剤で十分な効果が得られない患者に向けNaurexによって開発が進められています。GLYX-13の作用機序は完全に判明はしていませんが、シナプス可塑性を強化することにより抗うつ効果を引き出すのではないかという仮説が立てられています。

当レポートでは、大うつ病性障害の治療薬であるGLYX-13について調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、売上予測などをまとめ、お届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状およびサブタイプ
  • 予後
  • QOL

第4章 疾病の管理

  • 症状と治療の概要

第5章 競合評価

  • 概要

第6章 機会とアンメットニーズ

  • 概要
  • より効果的な薬物療法
  • より良好な副作用プロファイル
  • 抗うつ効果の迅速な発現
  • 個別化医療のアプローチ

第7章 パイプライン分析

  • 概要
  • 臨床開発中の有望な薬剤

第8章 GLYX-13

  • 概要
  • 効能
  • 安全性
  • 投与と処方
  • 臨床および市場における潜在的な位置づけ
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC429DFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

GLYX-13 is being developed by Naurex as an adjunctive therapy for MDD in patients with an inadequate response to antidepressants. The exact MOA of GLYX-13 is not fully understood, but it is hypothesized that it exerts its antidepressant effects by enhancing synaptic plasticity (Naurex, press release, December 12, 2013). GLYX-13 is being developed for IV administration and there is evidence to suggest that the NMDA receptor ligands can demonstrate rapid antidepressant effects (Popp et al., 2013).

Scope

  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on GLYX-13 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for GLYX-13 for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of GLYX-13 performance
  • Obtain sales forecast for GLYX-13 from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Unmet Needs and Opportunities

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunities
  • 6.3. More Favorable Side Effect Profiles
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunities
  • 6.4. Rapid Onset of Antidepressant Effects
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunities
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunities

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. GLYX-13

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical and Commercial Positioning
  • 8.6. SWOT Analysis
  • 8.7. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed MDD Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Directors
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013
  • Table 6: Leading Treatments for MDD, 2013
  • Table 7: Unmet Needs and Opportunities in MDD
  • Table 8: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 9: Product Profile - GLYX-13
  • Table 10: GLYX-13 SWOT Analysis, 2014
  • Table 11: Global MDD Sales Forecasts ($m) for GLYX-13, 2013-2023
  • Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD - Phase IIb-III Pipeline, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 6: Clinical and Commercial Positioning of GLYX-13
Back to Top